生产企业：AstraZeneca
AstraZeneca's first-in-class IL-33-targeting biologic (anti-IL-33 monoclonal antibody, MEDI3506); the first IL-33-targeting biologic to demonstrate statistically significant and clinically meaningful reductions in COPD exacerbations.
AstraZeneca's first-in-class IL-33-targeting biologic (anti-IL-33 monoclonal antibody, MEDI3506); the first IL-33-targeting biologic to demonstrate statistically significant and clinically meaningful reductions in COPD exacerbations.
Anti-IL-33 monoclonal antibody. Tozorakimab binds IL-33 and inhibits both IL-33red and IL-33ox activity, blocking two distinct signalling pathways engaged in COPD: inflammation and epithelial dysfunction.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
